Clinical trial • Phase I • Oncology|Respiratory
Clinical trial in Non-small cell lung cancer|Respiratory tract diseases
Phase I trial for Non-small cell lung cancer|Respiratory tract diseases. None/Not specified-controlled. 15 participants.
Overview
- Trial Therapeutic Area
- Oncology|Respiratory
- Trial Disease
- Non-small cell lung cancer|Respiratory tract diseases
- Trial Stage
- Phase I
- Drug Modality
- Cell therapy|Small molecule|Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 14-10-2024
- First CTIS Authorization Date
- 15-11-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Netherlands.
- Comparator
- None/Not specified
- Target Sample Size
- 15
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 48
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 15
Netherlands
- Earliest CTIS Part Ii Submission Date
- 14-11-2024
- Latest Decision Or Authorization Date
- 09-07-2025
- Processing Time Days
- 237
- Number Of Sites
- 1
- Number Of Participants
- 15
Sites
- Site Name
- Leiden University Medical Center
- Department Name
- Pulmonology
- Principal Investigator Name
- Laurie Steinbusch
- Principal Investigator Email
- l.c.steinbusch@lumc.nl
- Contact Person Name
- Laurie Steinbusch
- Contact Person Email
- l.c.steinbusch@lumc.nl
- Number Of Participants
- 15
Sponsor
Primary sponsor
- Full Name
- Leids Universitair Medisch Centrum (LUMC)
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- ADAGRASIB for Advanced non-small cell lung cancer
- Durvalumab for Resectable non-small cell lung cancer (stage IIB–IIIB, N2)
- REPOTRECTINIB for Stage III/IV non-small cell lung cancer (ROS1-rearranged)
- NIRAPARIB for Pleural mesothelioma|Non-small cell lung cancer
- IBI3009 for Extensive-stage small cell lung cancer